2023-04-26 07:04:24 ET
- Alkermes press release ( NASDAQ: ALKS ): Q1 Non-GAAP EPS of $0.01 beats by $0.02 .
- Revenue of $287.6M (+3.3% Y/Y) beats by $6.41M .
-
Net sales of proprietary products for the quarter increased approximately 25% to $214.7 million, compared to $171.3 million for the same period in the prior year.
- Net sales of VIVITROL were $96.7 million, compared to $84.9 million for the same period in the prior year, representing an increase of approximately 14%.
- Net sales of ARISTADA i were $80.1 million, compared to $72.5 million for the same period in the prior year, representing an increase of approximately 10%.
- Net sales of LYBALVI were $38.0 million, compared to $13.9 million for the same period in the prior year, representing an increase of approximately 173%.
- Manufacturing and royalty revenues for the quarter were $72.9 million, compared to $105.2 million for the same period in the prior year.
For further details see:
Alkermes Non-GAAP EPS of $0.01 beats by $0.02, revenue of $287.6M beats by $6.41M